Iris Ventures led a seed funding round for Superlativa, a plant-based drug- and hormone-free supplement for stress, anxiety, and hormonal imbalances.WHO: Founded by Teresa Pueyo, Superlativa is a modern wellness brand dedicated to developing high-quality, nature-inspired, science-backed supplements that address key areas of health such as stress and hormonal balance, helping women feel truly “super.” Backed by over 400 pharmacists, Superlativa’s drug- and hormone-free products are grounded in rigorous research and validated by clinical studies, reaffirming its commitment to science, efficacy, and transparency.Iris Ventures is the manager of IRIS Fund I FCRE, a €100 million growth equity fund specializing in innovative consumer brands with next-generation technology solutions focused on the European and US markets.WHY: The investment will be used for further research and development, with a rollout to other countries planned over the next two to three years.IN THEIR OWN WORDS: “Superlativa is leading an innovative approach to stress and anxiety management, standing out in the market with an effective, natural and transparent solution, backed by a solid educational foundation for its consumers,” said Montse Suárez, founder and Managing Partner at Iris Ventures. “We are delighted to partner with Teresa and the Superlativa team to drive their growth and consolidate their success.”“We are excited to support Superlativa in developing high-quality, scientifically backed supplements that address the root cause of anxiety,” adds Marc Calzada, investor at Iris Ventures.